164 related articles for article (PubMed ID: 23002208)
1. Chemotherapeutic sensitivity of testicular germ cell tumors under hypoxic conditions is negatively regulated by SENP1-controlled sumoylation of OCT4.
Wu YC; Ling TY; Lu SH; Kuo HC; Ho HN; Yeh SD; Shen CN; Huang YH
Cancer Res; 2012 Oct; 72(19):4963-73. PubMed ID: 23002208
[TBL] [Abstract][Full Text] [Related]
2. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ
Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044
[TBL] [Abstract][Full Text] [Related]
3. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model.
Jørgensen A; Blomberg Jensen M; Nielsen JE; Juul A; Rajpert-De Meyts E
J Steroid Biochem Mol Biol; 2013 Jul; 136():238-46. PubMed ID: 23098692
[TBL] [Abstract][Full Text] [Related]
4. KRIBB53 binds to OCT4 and enhances its degradation through the proteasome, causing apoptotic cell death of OCT4-positive testicular germ cell tumors.
Jung J; Kim Y; Song J; Yoon YJ; Kim DE; Kim JA; Jin Y; Lee YJ; Kim S; Kwon BM; Han DC
Carcinogenesis; 2018 May; 39(6):838-849. PubMed ID: 29668859
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-Induced Depletion of OCT4-Positive Cancer Stem Cells in a Mouse Model of Malignant Testicular Cancer.
Pierpont TM; Lyndaker AM; Anderson CM; Jin Q; Moore ES; Roden JL; Braxton A; Bagepalli L; Kataria N; Hu HZ; Garness J; Cook MS; Capel B; Schlafer DH; Southard T; Weiss RS
Cell Rep; 2017 Nov; 21(7):1896-1909. PubMed ID: 29141221
[TBL] [Abstract][Full Text] [Related]
7. SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1α.
Ao Q; Su W; Guo S; Cai L; Huang L
Sci Rep; 2015 Nov; 5():16396. PubMed ID: 26548925
[TBL] [Abstract][Full Text] [Related]
8. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ
Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464
[TBL] [Abstract][Full Text] [Related]
9. Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity.
Mueller T; Mueller LP; Holzhausen HJ; Witthuhn R; Albers P; Schmoll HJ
Histochem Cell Biol; 2010 Aug; 134(2):197-204. PubMed ID: 20532795
[TBL] [Abstract][Full Text] [Related]
10. IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.
Selfe J; Goddard NC; McIntyre A; Taylor KR; Renshaw J; Popov SD; Thway K; Summersgill B; Huddart RA; Gilbert DC; Shipley JM
J Pathol; 2018 Feb; 244(2):242-253. PubMed ID: 29160922
[TBL] [Abstract][Full Text] [Related]
11. The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors.
Juliachs M; Muñoz C; Moutinho CA; Vidal A; Condom E; Esteller M; Graupera M; Casanovas O; Germà JR; Villanueva A; Viñals F
Clin Cancer Res; 2014 Feb; 20(3):658-67. PubMed ID: 24277456
[TBL] [Abstract][Full Text] [Related]
12. Influence of Nodal signalling on pluripotency factor expression, tumour cell proliferation and cisplatin-sensitivity in testicular germ cell tumours.
Harpelunde Poulsen K; Nielsen JE; Grønkær Toft B; Joensen UN; Rasmussen LJ; Blomberg Jensen M; Mitchell RT; Juul A; Rajpert-De Meyts E; Jørgensen A
BMC Cancer; 2020 Apr; 20(1):349. PubMed ID: 32326899
[TBL] [Abstract][Full Text] [Related]
13. [SENP1 induced protein deSUMO modification increased the chemotherapy sensitivity of endometrial cancer side population cells].
Yuan ML; Bai J; Li CY; Xue N; Chen XH; Sheng F; Liu XZ; Li P
Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1362-1368. PubMed ID: 36575788
[No Abstract] [Full Text] [Related]
14. A Genetically Engineered Mouse Model of Malignant Testicular Germ Cell Tumors.
Lyndaker AM; Pierpont TM; Loehr AR; Weiss RS
Methods Mol Biol; 2021; 2195():147-165. PubMed ID: 32852763
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin hypersensitivity of testicular germ cell tumors is determined by high constitutive Noxa levels mediated by Oct-4.
Gutekunst M; Mueller T; Weilbacher A; Dengler MA; Bedke J; Kruck S; Oren M; Aulitzky WE; van der Kuip H
Cancer Res; 2013 Mar; 73(5):1460-9. PubMed ID: 23302226
[TBL] [Abstract][Full Text] [Related]
16. PCPH expression is an early event in the development of testicular germ cell tumors.
Regadera J; Blánquez MJ; González-Peramato P; Nistal M; Miller JC; Tirado OM; Notario V
Int J Oncol; 2006 Mar; 28(3):595-604. PubMed ID: 16465363
[TBL] [Abstract][Full Text] [Related]
17. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
18. Seladin-1 and testicular germ cell tumours: new insights into cisplatin responsiveness.
Nuti F; Luciani P; Marinari E; Erdei E; Bak M; Deledda C; Rosati F; Mazzinghi B; Danza G; Stoop H; Looijenga LH; Peri A; Serio M; Krausz C
J Pathol; 2009 Dec; 219(4):491-500. PubMed ID: 19844922
[TBL] [Abstract][Full Text] [Related]
19. The chemosensitivity of testicular germ cell tumors.
Voutsadakis IA
Cell Oncol (Dordr); 2014 Apr; 37(2):79-94. PubMed ID: 24692098
[TBL] [Abstract][Full Text] [Related]
20. Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer.
Steinemann G; Dittmer A; Schmidt J; Josuttis D; Fähling M; Biersack B; Beindorff N; Jolante Koziolek E; Schobert R; Brenner W; Müller T; Nitzsche B; Höpfner M
Mol Oncol; 2019 Dec; 13(12):2679-2696. PubMed ID: 31583820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
